John Greene insider trades: CRISPR Therapeutics (CRSP) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 26, 2025 | CRSP | ↑ Buy | 7,000 | $44.85 | $314K | Direct | Feb 28, 2025 (2d) |
| Jan 26, 2024 | DFS | ↓ Sell | 35,191 | $106.51 | $3.7M | Direct | Jan 30, 2024 (4d) |
| Feb 15, 2022 | DFS | ↓ Sell | 4,443 | $127.95 | $568K | Direct | Feb 17, 2022 (2d) |
| Jan 27, 2020 | DFS | ↑ Buy | 3,377 | $73.84 | $249K | Direct | Jan 27, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRSP insiders
Open-market trades in the last 12 months
About John Greene's insider trades
John Greene is an insider at CRISPR Therapeutics (CRSP). Since Jan 27, 2020, John has reported 2 open-market purchases worth $563K and 2 sales worth $4.3M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (25 filings), shares withheld for taxes (12 filings), shares returned to the company (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRSP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.